Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review
- PMID: 34984579
- PMCID: PMC8726514
- DOI: 10.1208/s12248-021-00644-3
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review
Abstract
Over the past decade, artificial intelligence (AI) and machine learning (ML) have become the breakthrough technology most anticipated to have a transformative effect on pharmaceutical research and development (R&D). This is partially driven by revolutionary advances in computational technology and the parallel dissipation of previous constraints to the collection/processing of large volumes of data. Meanwhile, the cost of bringing new drugs to market and to patients has become prohibitively expensive. Recognizing these headwinds, AI/ML techniques are appealing to the pharmaceutical industry due to their automated nature, predictive capabilities, and the consequent expected increase in efficiency. ML approaches have been used in drug discovery over the past 15-20 years with increasing sophistication. The most recent aspect of drug development where positive disruption from AI/ML is starting to occur, is in clinical trial design, conduct, and analysis. The COVID-19 pandemic may further accelerate utilization of AI/ML in clinical trials due to an increased reliance on digital technology in clinical trial conduct. As we move towards a world where there is a growing integration of AI/ML into R&D, it is critical to get past the related buzz-words and noise. It is equally important to recognize that the scientific method is not obsolete when making inferences about data. Doing so will help in separating hope from hype and lead to informed decision-making on the optimal use of AI/ML in drug development. This manuscript aims to demystify key concepts, present use-cases and finally offer insights and a balanced view on the optimal use of AI/ML methods in R&D.
Keywords: Artificial intelligence; Clinical trial design; Drug development; Machine learning; Precision medicine; Predictive modeling; Probability of success; Risk-based monitoring.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Conflict of interest statement
Sheela K. was previously employed by Takeda Pharmaceuticals and is currently employed by Teva Pharmaceuticals (West Chester PA USA) during the development and revision of this manuscript. All other authors are employed by Takeda Pharmaceuticals during the development and revision of this manuscript.
Figures
Similar articles
-
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.Drug Discov Today. 2021 Oct;26(10):2226-2231. doi: 10.1016/j.drudis.2021.04.028. Epub 2021 May 7. Drug Discov Today. 2021. PMID: 33965571 Review.
-
The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review.AAPS PharmSciTech. 2024 Aug 15;25(6):188. doi: 10.1208/s12249-024-02901-y. AAPS PharmSciTech. 2024. PMID: 39147952 Review.
-
Trends of Artificial Intelligence (AI) Use in Drug Targets, Discovery and Development: Current Status and Future Perspectives.Curr Drug Targets. 2025;26(4):221-242. doi: 10.2174/0113894501322734241008163304. Curr Drug Targets. 2025. PMID: 39473198 Review.
-
Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics.OMICS. 2019 Nov;23(11):539-548. doi: 10.1089/omi.2019.0151. Epub 2019 Oct 25. OMICS. 2019. PMID: 31651216
-
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D.Drug Discov Today. 2025 Jan;30(1):104272. doi: 10.1016/j.drudis.2024.104272. Epub 2024 Dec 13. Drug Discov Today. 2025. PMID: 39675517 Review.
Cited by
-
Modelling patient drug exposure profiles in vitro to narrow the valley of death.Nat Rev Bioeng. 2024 Mar;2(3):196-197. doi: 10.1038/s44222-024-00160-x. Epub 2024 Feb 7. Nat Rev Bioeng. 2024. PMID: 38873361 Free PMC article. No abstract available.
-
Integrated analysis of m6A regulator-mediated RNA methylation modification patterns and immune characteristics in Sjögren's syndrome.Heliyon. 2024 Mar 29;10(7):e28645. doi: 10.1016/j.heliyon.2024.e28645. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38596085 Free PMC article.
-
Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing.Cancers (Basel). 2024 Apr 11;16(8):1463. doi: 10.3390/cancers16081463. Cancers (Basel). 2024. PMID: 38672545 Free PMC article. Review.
-
PPP1R14B as a potential biomarker for the identification of diagnosis and prognosis affecting tumor immunity, proliferation and migration in prostate cancer.J Cancer. 2024 Oct 21;15(20):6545-6564. doi: 10.7150/jca.101100. eCollection 2024. J Cancer. 2024. PMID: 39668827 Free PMC article.
-
The role of artificial intelligence in drug screening, drug design, and clinical trials.Front Pharmacol. 2024 Nov 29;15:1459954. doi: 10.3389/fphar.2024.1459954. eCollection 2024. Front Pharmacol. 2024. PMID: 39679365 Free PMC article. Review.
References
-
- Russell S, Norvig P. Artificial intelligence: a modern approach (4th edition), 2021; Pearson Series in Artificial Intelligence.
-
- Mitchell A, Sharma Y, Ramanathan S, Sethuraman V. Is data science the treatment for inefficiencies in clinical trial operations? White paper. https://www.zs.com/insights/is-data-science-the-treatment-for-inefficien....
-
- Dill KA and MacCallum JL. The protein-folding problem, 50 years on. Science. 2012;338(6110):1042–6. 10.1126/science.1219021. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous